《滬深兩市》上證半日跌0.2% 深成創板跌0.6%-1.3% 地產、中醫藥股逆市升
內地疫情仍然嚴峻,昨日(5日)新增本土確診病例1,383例,新增本土無症狀感染者19,089例。人民銀行今日(6日)進行100億元人民幣(下同)7天期逆回購操作,單日淨回籠4,400億元。人民幣兌美元中間價今下調290點。3月財新中國服務業PMI降至42遠遜預期,爲兩年來新低。上證深成創板低開後走勢偏弱,上證低位有支持,跌幅較爲輕微,創板走勢較差跌逾1%。
上證半日微跌7點或0.2%,收報3,275點;深成指跌74點或0.6%,收報12,153點;創業板指數跌1.3%或35點,收報2,631點,成交1,131億元。上證深成半日成交分別爲2,647億元及3,403億元。
中資金融股偏好,工行(601398.SH)及建行(601939.SH)分別升0.8%及0.3%。
地產股逆市上升,中交地產(000736.SZ)漲停。萬科A(000002.SZ)升3.5%。招商蛇口(001979.SZ)高開高走升4.8%,公司與長城資產及佳兆業(01638.HK)籤戰略合作協議。吳向東辭任華夏幸福(600340.SH)董事長、首席執行官及總裁等職務。該股漲停。
據報中醫藥治療新冠療效獲世衛組織認可,帶動中醫藥股造好,香雪製藥(300147.SZ)、大理藥業(603963.SH)及以嶺藥業(002603.SZ)均漲停。
隆基股份(601012.SH)新電池技術預計在第四季度量產,股價跌5.5%。寧德時代(300750.SZ)德國工廠獲得電芯生產許可,惟股價跌2%。贛鋒鋰業(002460.SZ)先升後跌1.9%,公司參與Mt Marion項目擴建,計劃年內將鋰精礦產能擴張至每年達90萬噸。
比亞迪(002594.SZ)升3.6%。比亞迪澄清漲價傳聞稱屬不實消息。(ta/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.